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Abstract
Background: Mortality in patients with cardiogenic shock (CS) due to acute myocardial
infarction (MI) may be decreased by fibrynolytic therapy combined with intraaortic balloon
counterpulsation or by invasive treatment, either with percutaneous coronary intervention (PCI)
or coronary artery bypass grafting (CABG). The aim of the study was to compare in-hospital
and long-term outcomes in patients with acute MI complicated by CS who were treated with
primary or facilitated PCI.
Methods: Among 98 consecutive patients with acute MI complicated by CS, 93 patients were
treated with PCI and 5 patients underwent CABG. Patients treated with PCI were divided
into two groups: group I included 59 patients treated with facilitated PCI and group II
included 34 patients treated with primary PCI. Patients in group II were older, had higher
systolic and diastolic blood pressure, and more often presented with 1-vessel disease and
previous MI, while 3-vessel disease was more common in group I (all p < 0.05).
Results: Immediate PCI success rate was similar in both groups (83% in group I vs. 74% in
group II, p = NS), as was in-hospital mortality (41% vs. 36%, respectively, p = NS) and
mortality rate in the cardiac cathetherization laboratory (20% vs. 15%, respectively, p = NS).
The need for repeated PCI was significantly more common in group I (22% vs. 3%, p = 0.02).
The two groups did not differ with respect to the need for CABG or the rate of hemorrhagic
complications. During one year follow-up, three deaths occurred in every group, including two
patients in each group who died suddenly.
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Conclusions: Comparable immediate PCI success rate, in-hospital mortality, and long-term
mortality were seen in patients with acute MI complicated by CS treated with primary or
facilitated PCI. More coronary reinterventions were needed in patients treated with facilitated
PCI compared to those treated with primary PCI. (Folia Cardiol. 2006; 13: 384–389)
Key words: acute myocardial infarction, cardiogenic shock, primary percutaneous
coronary intervention, facilitated percutaneous coronary intervention
Introduction
Cardiogenic shock (CS) is currently the major
cause of death of patients with acute myocardial
infarction (AMI) [1]. Some reports suggest that
fibrinolytic therapy (FT) in patients with AMI might
be associated with decreased incidence of CS [2, 3].
On the other hand, FT does not affect mortality in
patients with AMI and established CS [4]. Mortali-
ty in patients with AMI complicated by CS may be
decreased by FT combined with intraaortic balloon
counterpulsation (IABP) or by invasive treatment,
either with percutaneous coronary intervention (PCI)
or coronary artery bypass grafting (CABG) [5–9].
The role of FT in patients with AMI complicated
by CS undergoing coronary angioplasty has not been
defined. In particular, it is unclear whether FT sho-
uld be administered in patients with established CS
referred for PCI.
The aim of the study was: to compare imme-
diate success rate and complications of primary
versus facilitated PCI in patients with AMI compli-
cated by CS, and to evaluate in-hospital and long-
term mortality in these patients depending on whe-
ther they were revascularized with primary or fa-
cilitated PCI.
Methods
We studied 98 patients hospitalized in our cen-
ter between January 1991 and October 1999 due to
AMI within 6 hours from the onset of chest pain.
Ninety-three patients were treated with PCI and
5 patients with left main coronary artery disease un-
derwent CABG. Inclusion criteria, patient manage-
ment on admission and in the cardiac catheteriza-
tion laboratory, and details of long-term follow-up
were presented previously [10]. Only patients un-
dergoing PCI were included in the present analy-
sis. Patients were divided into two groups: group I
included patients treated with PCI following FT
with streptokinase, i.e. fulfilling the current crite-
ria of facilitated PCI, and group II included patients
treated with primary PCI. The administration of FT
in the referring hospital was left at the discretion
of the treating physician, taking into account con-
traindications to FT and expected patient transfer
time. The decision to administer FT was often made
after a telephone consultation with a physician in
our center. FT was initiated in the referring hospi-
tal and continued until angioplasty. Immediate PCI
success was defined as TIMI 2–3 flow with < 50%
residual stenosis [9].
Statistical analysis
Results are expressed as mean values ± stan-
dard deviation (SD) for continuous variables and
numbers and percentages for categorical variables.
Distribution of continuous variables was evaluated
using Shapiro-Wilk test. Statistical significance of
the differences in normally distributed continuous
variables between the two groups was evaluated
using Student t test. Categorical variables were
compared using c2 test. Long-term survival in the
two groups was evaluated using Kaplan-Meyer cu-
rves. Statistical significance of the differences in
survival between the two groups was tested using
Cox proportional hazards model. P<0.05 was con-
sidered statistically significant.
Results
Group I consisted of 59 patients (63%) inclu-
ding 43 men (73%), and group II consisted of
34 patients (37%) including 22 men (65%). Mean
age was 53.2 years in group I compared to 61.7 years
in group II (p < 0.004). Similarly, there were signi-
ficantly more patients aged > 70 years in group II.
Demographic and clinical characteristics of the two
groups is shown in Table 1. The two groups differed
significantly in systolic and diastolic blood pressure
on admission (78/54 mm Hg in group I vs. 70/46 mm Hg
in group II). Three-vessel disease was significantly
more common in group I (34% vs. 12% in group II),
while 1-vessel disease was significantly more com-
mon in group II (53% vs. 29% in group I). All patients
in group I received streptokinase. Immediate PCI
success rata was higher in group I (83%) than
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Table 1. Demographic, clinical and angiographic characteristics of patients.
Variable Overall Facilitated PCI Primary PCI p
(n = 93) (n = 59) (n = 34)
Age (years) 56.0 ±11.2 53.2 ± 10.0 61.7 ± 11.5 < 0.004
Age > 70 years 9 (10%) 1 (2%) 8 (24%) < 0.002
Female 28 (30%) 16 (27%) 12 (35%) NS
Male 65 (70%) 43 (73%) 22 (65%) NS
Hypertension 42 (45%) 28 (47%) 14 (41%) NS
Diabetes 18 (19%) 10 (17%) 8 (24%) NS
Smoking 59 (63%) 41 (69%) 18 (53%) NS
Hypercholesterolemia 28 (30%) 17 (28%) 11 (32%) NS
Previous myocardial infarction 19 (20%) 8 (13%) 11 (32%) 0.03
Time from onset of chest pain [h] 3.9 ±1.6 4.0 ± 1.6 3.6 ± 1.7 NS
Site of myocardial infarction:
anterior wall 55 (59%) 32 (54%) 23 (68%) NS
inferior wall 38 (41%) 27 (46%) 11 (32%) NS
Pulmonary edema on admission 19 (20%) 14 (24%) 5 (15%) NS
Inotropic support on admission 61 (66%) 39 (66%) 22 (64%) NS
Systolic blood pressure on admission 75.2 ±12.6 77.9 ± 11.0 70.4 ± 13.2 < 0.005
Diastolic blood pressure on admission 51.2 ±13.0 54.4 ± 13.3 46.0 ± 16.7 < 0.006
Need for temporary pacing 28 (33%) 14 (24%) 14 (41%) NS
Need for defibrillation in cath lab 18 (21%) 10 (17%) 8 (24%) NS
Need for external chest massage in cath lab 24 (26%) 13 (22%) 11 (32%) NS
Need of ventilatory support in cath lab 28 (33%) 16 (27%) 12 (35%) NS
Intraaortic balloon counterpulsation 33 (35%) 22 (37%) 11 (32%) NS
Extent of coronary artery disease:
1-vessel 35 (38%) 17 (29%) 18 (53%) 0.02
2-vessel 34 (36%) 22 (37%) 12 (35%) NS
3-vessel 24 (26%) 20 (34%) 4 (12%) 0.02
Culprit vessel:
left main 6 (6%) 4 (7%) 2 (6%) NS
left anterior descendings 45 (49%) 25 (42%) 20 (59%) NS
left circumflex 9 (10%) 8 (14%) 1 (3%) NS
right coronary artery 33 (35%) 22 (37%) 11 (32%) NS
TIMI flow before percutaneous
coronary intervention
TIMI 0 72 (77%) 44 (75%) 28 (82%) NS
TIMI 1 6 (7%) 3 (5%) 3 (9%) NS
TIMI 2 10 (11%) 8 (13%) 2 (6%) NS
TIMI 3 5 (5%) 4 (7%) 1 (3%) NS
TIMI flow after percutaneous
coronary intervention
TIMI 0 14 (15%) 7 (12%) 7 (20%) NS
TIMI 1 2 (2%) 1 (2%) 1 (3%) NS
TIMI 2 7 (8%) 4 (7%) 3 (9%) NS
TIMI 3 70 (75%) 47 (79%) 23 (68%) NS
Use of balloon perfusion cathethers 11 (12%) 7 (12%) 4 (12%) NS
Use of stents 14 (15%) 11 (19%) 3 (9%) NS
in group II (74%) but the difference was not signifi-
cant (Table 2). In-hospital mortality was higher in
group II (41% vs. 36% in group I), and mortality rate
in the cardiac cathetherization laboratory was
higher in group I (20% vs. 15% in group II) but these
differences were not significant. The need for repe-
ated PCI during in-hospital follow-up was significan-
tly more common in group I (22% vs. 3%, p = 0.02).
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PCI was repeated due to symptomatic restenosis in
3 patients in group I, and due to symptomatic reocclu-
sion in the remaining 11 patients (including 10 patients
in group I and 1 patient in group II). Five patients
underwent repeat PCI during the first day, and the
remaining patients in the subsequent days of hospi-
talization. The two groups did not differ with respect
to the need for CABG required or the rate of hemor-
rhagic complications requiring transfusion. During one
year follow-up, three deaths occurred in every gro-
up, including two patients in each group who died sud-
denly from cardiac causes. Figure 1 shows Kaplan-
-Meier survival curves.
Discussion
The use of FT is associated with the decreased
incidence of CS [2, 3]. Primary PCI may also redu-
ce the incidence of CS but no randomized studies
comparing primary PCI with medical management
in patients with AMI are available [11]. Some re-
ports suggest decreased mortality in patients with
AMI complicated by CS treated with FT and IABP
[5–8]. Available data from the literature do not cla-
rify the role of FT in patients undergoing revascu-
larization. In a study by Berger et al. [12], who ana-
lyzed patients with CS in the GUSTO I trial, early
coronary angiography and invasive treatment (PCI/
/CABG), if needed, were shown to decrease mor-
tality compared to late or no coronary angiography.
Sanborn et al. analyzed data from the SHOCK regi-
stry and suggested that the use of FT, IABP, and
PCI/CABG in CS is associated with decreased mor-
tality compared to medical management. With FT,
mortality was decreased (54% vs. 64%, p = 0.005)
regardless of the use of IABP. Significant differen-
ces in mortality were found between all four gro-
ups of patients (FT + IABP: 47%; IABP only: 52%;
FT only: 63%; no FT and IABP: 77%), and invasive
strategies were associated with improved survival in
each groups [13]. The authors noted that these results
may have been influenced by patient selection. In ad-
dition, they concluded that the best strategy to treat
patients with AMI complicated by CS in a hospital wi-
thout interventional facilities is probably to initiate FT,
start IABP, and transfer the patient to a hospital with
a cardiac cathetherization laboratory [13]. Our findings
show comparable immediate PCI success rate, in-ho-
spital mortality, and long-term mortality in patients with
AMI complicated by CS treated with primary or facili-
tated PCI. Similar findings were shown in the SHOCK
trial that showed no additional benefit from FT in pa-
tients undergoing invasive treatment (PCI/CABG).
In this randomized study, patients were randomly as-
signed to initially conservative or initially invasive tre-
atment but not to FT or no FT. This study also sho-
wed the improved survival with FT in patients initial-
ly treated conservatively (with most patients also
treated with IABP) [14].
Table 2. Selected outcomes in patients treated with primary and facilitated percutaneous coronary
intervention.
Outcome Facilitated PCI Primary PCI p
(n = 59) (n = 34)
Immediate angioplasty success (effective reperfusion) 49 (83%) 25 (74%) NS
In-hospital deaths 21 (36%) 14 (41%) NS
Deaths in the cath lab 12 (20%) 5 (15%) NS
Need for repeated angioplasty 13 (22%) 1 (3%) 0.02
Hemorrhagic complications requiring transfusion 5 (9%) 3 (9%) NS
Need for coronary artery bypass grafting 4 (7%) 3 (9%) NS
Figure 1. Kaplan-Meier cumulative survival curves in
groups treated with primary and facilitated percutane-
ous coronary intervention.
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In our study, the two groups of patients diffe-
red significantly in age and blood pressure on ad-
mission. Similar differences were seen by French
et al. [14] who showed that patients treated with
FT were younger and had higher blood pressure but
that study compared patients treated invasively or
conservatively, and in our study all patients under-
went angioplasty. Our findings also show no signi-
ficant difference in the rate of hemorrhagic compli-
cations requiring transfusion. Similarly, no differen-
ce in the rate of hemorrhagic complications was
seen between patients receiving FT or no FT in the
invasive group (PCI/CABG) in the study by French
et al. [14] (36% vs. 36%). The rates of hemorrhagic
complications in the latter trial were higher than in
our study, most likely due to differences in the use
of IABP. In our study, the use of IABP was less fre-
quent, while nearly all patients in the SHOCK trial
received IABP [14]. The study by French et al. [14]
also suggests that the use of IABP in the invasive
group significantly increases the rate of hemorrha-
gic complications — from 11% to 33% in patients
not receiving FT and from 18% to 40% in patients
receiving FT. Our findings, similarly to the study
by French et al. [14], do not suggest that patients
with AMI complicated by CS who are referred for
invasive treatment, should additionally receive FT,
as the latter seems to be associated with no addi-
tional benefits. Until now, no randomized studies
have evaluated FT in patients with AMI complica-
ted by CS who are treated invasively. Both in the
study by French et al. [14] and in our study some
patients received FT prior to the occurrence of CS
but precise data regarding the percentage of such
patients in our study is missing. In summary, our
study shows that in patients with AMI complicated
by CS who are treated invasively, FT does not im-
prove survival but it is also not associated with in-
creased risk of hemorrhagic complications.
Despite the use of FT in some patients we saw
no difference in the rate of TIMI 2–3 flow in the in-
itial angiogram. The rates of TIMI 2–3 flow before
PCI in patients treated with facilitated or primary
PCI in our study (20% vs. 9%, p = NS) were lower
than in the study by French et al. [14] (58% vs. 43%,
respectively, p = 0.03) [14]. Although no significant
differences were shown in our analysis, lower
percentage of patients with TIMI 2–3 flow in our
study may be explained by shorter time from the
onset of AMI to admission and coronary angiogra-
phy compared to the SHOCK trial.
Main limitations of our study included lack of
randomization to the evaluated strategies, single
center nature of the study, and low numbers of
patients in the study groups. In addition, low use of
stents, in contrast to the current clinical practice,
might have affected the rate of repeated PCI.
Conclusions
1. Comparable immediate PCI success rate, in-
hospital mortality, and long-term mortality
were seen in patients with AMI complicated by
CS treated with primary or facilitated PCI.
2. More coronary reinterventions were needed in
patients treated with facilitated PCI compared
to those treated with primary PCI, while the
rate of hemorrhagic complications requiring
transfusion was similar in the two groups.
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